These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16953197)

  • 21. Regulatory approaches to worker protection in nanotechnology industry in the USA and European union.
    Murashov V; Schulte P; Geraci C; Howard J
    Ind Health; 2011; 49(3):280-96. PubMed ID: 21372443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Issues and concerns in nanotech product development and its commercialization.
    Kaur IP; Kakkar V; Deol PK; Yadav M; Singh M; Sharma I
    J Control Release; 2014 Nov; 193():51-62. PubMed ID: 24933600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulating interface science healthcare products: myths and uncertainties.
    Bravery CA
    J R Soc Interface; 2010 Dec; 7 Suppl 6(Suppl 6):S789-95. PubMed ID: 20861040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Governance strategies for living technologies: bridging the gap between stimulating and regulating technoscience.
    van Est R; Stemerding D
    Artif Life; 2013; 19(3-4):437-50. PubMed ID: 23834596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA's evolving approach to nanotechnology.
    Monica JC
    Food Drug Law J; 2012; 67(4):405-11, i. PubMed ID: 24640614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanotechnology: A little knowledge..
    Brumfiel G
    Nature; 2003 Jul; 424(6946):246-8. PubMed ID: 12867950
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA holds public meeting on nanotechnology.
    Traynor K
    Am J Health Syst Pharm; 2006 Nov; 63(22):2175-7. PubMed ID: 17090732
    [No Abstract]   [Full Text] [Related]  

  • 28. Nanotech insight.
    Amabilino DB
    Small; 2005 Aug; 1(8-9):782-5. PubMed ID: 17193523
    [No Abstract]   [Full Text] [Related]  

  • 29. Does nanotech have a gender?
    Toumey C
    Nat Nanotechnol; 2012 Jul; 7(7):412. PubMed ID: 22760017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technology: Nanomaterials need flexible regulation.
    Wickson F
    Nature; 2011 Aug; 476(7360):283. PubMed ID: 21850092
    [No Abstract]   [Full Text] [Related]  

  • 31. Is nanotechnology too broad to practise?
    Drezek RA; Tour JM
    Nat Nanotechnol; 2010 Mar; 5(3):168-9. PubMed ID: 20203616
    [No Abstract]   [Full Text] [Related]  

  • 32. Transnational models for regulation of nanotechnology.
    Marchant GE; Sylvester DJ
    J Law Med Ethics; 2006; 34(4):714-25. PubMed ID: 17199813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanotech is not so scary.
    Nature; 2003 Jan; 421(6921):299. PubMed ID: 12540857
    [No Abstract]   [Full Text] [Related]  

  • 34. Commercialization of nanotechnology.
    Hobson DW
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(2):189-202. PubMed ID: 20049790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commentary: Is it possible to determine the extent to which informational asymmetries and prejudice bias responses?
    Hurley T
    J Law Med Ethics; 2009; 37(4):594-7. PubMed ID: 20122102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing U.S. oversight strategies for nanobiotechnology: learning from past oversight experiences.
    Paradise J; Wolf SM; Kuzma J; Kuzhabekova A; Tisdale AW; Kokkoli E; Ramachandran G
    J Law Med Ethics; 2009; 37(4):688-705. PubMed ID: 20122110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

  • 38. Applying the marketing mix (5 ps) to bionanotechnology.
    Tomczyk MS
    Methods Mol Biol; 2011; 726():393-411. PubMed ID: 21424463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Commentary: Emerging technologies oversight: research, regulation, and commercialization.
    Johnson R
    J Law Med Ethics; 2009; 37(4):587-93. PubMed ID: 20122101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating oversight systems for emerging technologies: a case study of genetically engineered organisms.
    Kuzma J; Najmaie P; Larson J
    J Law Med Ethics; 2009; 37(4):546-86. PubMed ID: 20122100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.